Nexentis Technologies Inc. (NXTS)
| Market Cap | 3.61M -14.1% |
| Revenue (ttm) | n/a |
| Net Income | -9.39M |
| EPS | -31.47 |
| Shares Out | 730.19K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 269,938 |
| Open | 4.270 |
| Previous Close | 4.460 |
| Day's Range | 4.186 - 6.250 |
| 52-Week Range | 3.380 - 89.793 |
| Beta | 1.74 |
| Analysts | Strong Buy |
| Price Target | 9,432.52 (+190,841.7%) |
| Earnings Date | May 29, 2026 |
About NXTS
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company’s pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for NXTS stock is "Strong Buy" and the 12-month stock price target is $9,432.52.
News
Nexentis Technologies says MitoCareX Bio achieves drug discovery milestone
Nexentis Technologies (NXTS) announced that its wholly owned subsidiary, MitoCareX Bio achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit...
Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on...
Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone
MITOLINE ® -Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development
Nexentis Technologies Inc trading halted, volatility trading pause
09:30 EDT Nexentis Technologies (NXTS) Inc trading halted, volatility trading pause
Nexentis Technologies Inc trading resumes
09:35 EDT Nexentis Technologies (NXTS) Inc trading resumes
Nexentis Technologies announces Mitoline U.S. trademark registration approval
Nexentis Technologies (NXTS) announced that its wholly owned subsidiary, MitoCareX Bio, has received official trademark registration from the USPTO for its proprietary algorithm platform, Mitoline. Mi...
Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX's Algorithm Platform MITOLINE™
Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” or the “Company”), a drug discovery company that is also invests in solar energy assets base...
Nexentis Technologies files $100M mixed securities shelf
16:18 EDT Nexentis Technologies (NXTS) files $100M mixed securities shelf
Nexentis Technologies Inc trading halted, news pending
19:50 EDT Nexentis Technologies (NXTS) Inc trading halted, news pending
Nexentis Technologies launches new corporate website
Nexentis Technologies (NXTS) announced the launch of its new corporate website at www.nexentistech.com. This digital milestone follows the company’s recent rebranding from N2OFF, Inc., and underscores...
N2OFF, Inc. Provides Early Warning Disclosure
Vancouver, British Columbia, February 19, 2026 – TheNewswire – This press release is being disseminated as required b y National Instrument 62-103 The Early Warning System and Related Take-Over Bid a...
In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions
Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (...
N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform
MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030
N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions
Neve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (R...
N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake
Neve Yarak, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (R...
N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy
Neve Yarak, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) bus...
N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination
Neve Yarak, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, follo...
N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers
Neve Yarak, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) bus...
N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
Neve Yarak, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) bus...
N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
Neve Yarak, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) bu...
N2OFF Provides Business Update on Successful Execution of Solar and Energy Storage Initiatives Across Europe
Neve Yarak, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) bu...
N2OFF to Expand its Melz Solar Project with Battery Storage
According to Entrix , the project's expansion is projected to boost the project's revenue, potentially paving the way for higher returns to N2OFF's stockholders.
N2OFF Completes $1.2 million of its $2.7 million Total Commitment to Finance 196MWp Battery Energy Storage Assets in Italy
According to industry sources , “Ready to Build” battery storage projects of this capacity may yield up to $13.5 million
N2OFF is Increasing its Investment in Melz Project to Explore Additional 40-60 MW Battery Storage
Neve Yarak, Israel, June 16, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.(NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable and innovative solutions for solar en...
N2OFF Energy Targets European's Energy Crises with Fourth Regional Battery Project
N2OFF to take part in financing a 35MW/140MWh planned Battery Energy Storage System project in Poland Neve Yarak, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.(NASDAQ: NITO) (FSE:80W) (“N2OFF” ...